SCIENTIFIC PROGRAMME
Thursday, September 22, 2022
09.00 Registration Opens
10.00 – 10.10 Welcome Address
10.10 – 11.40 Plenary Symposium 1: Emerging Concepts / New Agents (including Immunometabolism)
Chair: Stefan Endres, Munich, Germany & Gabriela Wiedemann, Munich, Germany
10.10 – 10.40 01.01 Dissecting and modulating reactive anti-tumor immunity in human cancer
Daniela Thommen, Amsterdam, The Netherlands
10.40 – 11.10 01.02 CH13L1: a novel NK cell related immune check point
Maria Rescigno, Pieve Emanuele (Milano), Italy
11.10 – 11.40 01.03 Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors
for elimination by checkpoint blockade
Marisol Soengas, Madrid, Spain
11.40 – 13.10 Plenary Symposium 2: Tumor microenvironment and microbiome
Chair: Marcus Bosenberg, New Haven, CT, USA & Michael Bergmann, Vienna, Austria
11.40 – 12.10 02.01 Investigating the impact of lymphatic transport in immunotherapy
Amanda Lund, New York, NY, USA
12.10 – 12.40 02.02 Immune cell communications in the tumor microenvironment
Thorsten Mempel, Boston, MA, USA
12.40 – 13.10 02.03 Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor
microenvironment
Romina Goldszmid, Bethesda, MD, USA
13.10 – 14.00 Lunch
14.00 – 15.00 Satellite Symposium
15.00 – 15.30 Coffee Break
15.30 – 17.30 Plenary Symposium 3: B cells in immunooncology
Chair: Mascha Binder, Halle, Germany & Eric Tartour, Paris, France
15.30 – 16.00 03.01 From B cells to tertiary lymphoid structures in NSCLC patients
Marie-Caroline Dieu-Nosjean, Paris, France
16.00 – 16.30 03.02 Neoantigen-driven B cells promote CD8 T cell responses
Nikhil Joshi, New Haven, CT, USA
16.30 – 17.00 03.03 Engineering B cells for cancer treatment
Adi Barzel, Tel Aviv, Israel
17.00 – 17.15 03.04 Towards a B cell Vaccine for Tumour expressed Self-Antigens
Fernanda Escobar-Riquelme, Birmingham, United Kingdom
17.15 – 17.30 03.05 Understanding how epitope binding influences antibody dependent complement engagement for
therapy of B-cell malignancies
Sina Bondza, Uppsala, Sweden
17.30 - 19.00 Welcome Reception and Poster Viewing (at the venue)
Friday, September 23, 2022
08.30 – 09.30 Plenary Symposium 4: Vaccine Therapy
Chair: Niroshana Anandasabapathy, New York, United States & Tanja de Gruijl, Amsterdam, The Netherlands
08.30 - 09.00 04.01 IDH directed vaccines in Glioblastoma
Michael Platten, Heidelberg, Germany
09.00 - 09.30 04.02 The generation of immunostimulatory exosomes programmed by oncolytic viruses
Brian Lichty, Toronto, ON, Canada
09.30 – 10.30 Plenary Symposium 5: Pro & Contra Sessions for Critical Topics
Chair: Florian Bassermann, Munich, Germany & TBA
09.30 – 10.00 05.01 Pro IO combination with chemotherapy
Mascha Binder, Halle, Germany
10.00 – 10.30 05.02 Contra: IO mono- or combo-therapy shall prevail
Stéphane Champiat, Villejuif, France
10.30 – 11.00 Coffee Break
11.00 – 12.00 Satellite Symposium
12.00 – 13.30 Plenary Symposium 6: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
Chair: Pedro Romero, Lausanne, Switzerland & Chong Xian Pan, Boston, MA, USA
12.00 – 12.30 06.01 Single cell and spatial transcriptomics unravel a NASH-associated innate immunity contexture in
hepatocellular carcinoma associated with poor response to immunotherapy
Maya Saleh, Bordeaux, France
12.30 – 13.00 06.02 Using PET to Image Immune Cell Changes in Response to Therapy
Elisabeth de Vries, Groningen, The Netherlands
13.00 – 13.15 06.03 Integrative analysis of neuroblastoma by single‐cell RNA sequencing identifies the NECTIN2‐TIGIT axis
as a target for immunotherapy
Judith Wienke, Utrecht, The Netherlands
13.15 – 13.30 06.04 Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Chong-Xian Pan, Boston, MA, USA
13.30 – 14.30 Lunch
14.30 – 15.00 Satellite Symposium
Please click HERE for details
15.00 – 15.45 Plenary Symposium 7: Lifetime Achievement Award presented to Prof. Dr. Laurence Zitvogel
Chair: Michael von Bergwelt, Munich, Germany & Christoph Zielinski, Vienna, Austria
07.01 Microbiota-centered Interventions to circumvent primary resistance to I-O
Laurence Zitvogel, Villejuif, France
15.45 – 16.15 Coffee Break
16.15 – 17.30 Plenary Symposium 8: “Lost in Translation”
Chair: Bastian Schilling, Würzburg, Germany & Maya Saleh, Bordeaux, France
16.15 – 16.45 08.01 Will vaccination strategies come back of age in melanoma?
Tanja de Gruijl, Amsterdam, The Netherlands
16.45 – 17.15 08.02 What T cells see in context of immunotherapy
Sine Reker Hadrup, Lyngby, Denmark
17.15 – 17.30 08.03 MHJC-based large-scale screening of anti-tumor T cells in chronic lymphocytic leukemia reveals CD8+ T
cells with specificity against the clonotypic B-cell receptor immunoglobulin
Yogesh Basavaraju, Copenhagen, Denmark
17.30 – 18.30 Plenary Session 9: Young Researcher Session (from submitted abstracts)
Chair: Sebastian Kobold, Munich, Germany & Volkmar Nüssler, Munich, Germany
17.30 – 17.45 09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b
receptor (DNR) to enable efficacy in solid tumor models
Thaddäus Strzalkowski, Munich, Germany
17.45 – 18.00 09.02 Bispecific antibodies enable synthetic agonistic receptor T cell therapy in melanoma
Florian Märkl, Munich, Germany
18.00 – 18.15 09.03 CD122-directed IL-2/anti-IL-2 complexes enhance abscopal responses to radiation combined with anti-
PD-1
Kateryna Onyshchenko, Freiburg, Germany
18.15 – 18.30 09.04 Secondary resistance to immunotherapy is associated with death and de-differentiation of activated T
Cells
Chen Qing, London, United Kingdom
18.30 Poster Viewing with Presenters
20.00 ITOC9 Conference Dinner
Saturday, September 24, 2022
08.00 – 09.00 Plenary Symposium 10: Cell Therapy in Solid Tumors
Chair: Philipp Beckhove, Regensburg, Germany & TBA
08.00 – 08.30 10.01 Reengineering CAR T cells for optimized efficacy in solid tumors
TBA
08.30 – 09.00 10.02 Enabling CAR T cells in solid tumors by check point blockade
Prasad Adusumilli, New York, NY, USA
09.00 – 09.30 Satellite Symposium
09.30 – 11.00 Plenary Symposium 11: Cell Therapy in Haematologic Diseases
Chair: Marion Subklewe, Munich, Germany & Tobias Feuchtinger, Munich, Germany
09.30 – 10.00 11.01 Single-cell approaches for identifying antigen dependent and independent toxicity in BiTEs and CAR T
cells
Caleb Lareau, Standford, CA, USA
10.00 – 10.30 11.02 Novel approaches to cell therapy of myeloma
Andrea Schmidts, Munich, Germany
10.30 – 11.00 11.03 T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Johanna Olweus, Oslo, Norway
11.00 – 11.30 Coffee Break
11.30 – 12.30 Plenary Symposium 12: Combination Therapy (with a special focus on local IO)
Chair: José Saro, Abingdon, United Kingdom & Fabian Müller, Erlangen, Germany
11.30 – 12.00 12.01 Local low-dose RT to address anti-PD-1 resistance
James Welsh, Houston TX, USA
12.00 – 12.30 12.02 Local immune modulation and tumor ablation
Gosse Adema, Nijmegen, The Netherlands
12.30 – 12.45 12.03 ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of
CD38 positive hematological malignancies
Stefano Sammicheli, Lausanne, Switzerland
12.45 – 13.00 12.04 Re-directing CAR-T cells against solid tumors using T-SIGn-mediated antigen delivery and tumor
microenvironment reprogramming
Maria Sasso, Abingdon, United Kingdom
13.00 – 13.15 12.05 Tumor targeted innate immune checkpoint blockade for the treatment of Neuroblastoma using
Bifunctional antibodies
Fabian Schuurmans, Nijmegen, The Netherlands
13.15 – 13.30 Best Poster Awards & Closing Remarks
13.30 – 14.30 Lunch